Top news of the week: 09.11.2021.
Healthcare
OICR-JLABS cancer symposium series
November 17 from 10-11:30 a.m. ET Oncolytic (cancer-killing) viruses are one of the most promising forms of immunotherapy today because they can effectively target and destroy cancer cells ...
Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
The dosing of the first patient in this study marks a meaningful step to developing a potential future treatment for cancer patients with limited options," said Patricia …
Mapping conflict of interests: scoping review
Objective To identify all known ties between the medical product industry and the healthcare ecosystem. Design Scoping review. Methods From initial literature searches and expert input, a ...
Psychedelic Drug Trials Accelerate as Decriminalization Spreads, Investment Expands
McAlinden Research Partners estimates it may be only a matter of time before psychedelics become part of a biotech boom.
Democrats circulate a new drug pricing outline with a big carveout for small biotechs
A drug pricing compromise circulating on Capitol Hill and in lobbying circles this week includes a generous carveout for small biotechs.
Galapagos reports commercial and operational progress at Q3 financial results
First nine months 2021 financial results: Group revenues of €317.9 millionOperating loss of €175.7 millionNet loss of €119.6 millionCash and current...
The Startling History Behind Merck's New Cancer Blockbuster
The success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly ...
SLT Company's 'Cell Replacement in a Bottle' a Powerful Option in Treating Genetic Diseases Research Report
BTIG commented in a research report that Sigilon Therapeutics is developing a powerful and widely applicable cell replacement in a bottle as a potential functional cure for genetic ...